Policy

PYC Therapeutics (ASX:PYC) has presented data supporting the progress made in its PYC002 program at the Phelan-McDermid Syndrome Global Congress to be held in Spain.

Percheron Therapeutics (ASX:PER) has entered into a worldwide exclusive license agreement with Hummingbird Bioscience, a venture-backed biotechnology company based in Singapore, for HMBD-002, a monoclonal antibody therapy with potential applications in various cancer indications.

QBiotics chair, Mark Fladrich, said, “On behalf of my fellow directors, we are delighted to welcome Sergio to the Board of QBiotics."

Arovella Therapeutics (ASX:ALA) has announced that Dr Thomas Duthy is retiring effective 1 July as a non-executive director and chairman of the company to pursue new business opportunities.

Tetratherix (ASX:TTX) has officially listed on the Australian Securities Exchange after raising $25 million in its initial public offering.

LTR Pharma (ASX:LTP) has announced that it has achieved its latest regulatory milestone for SPONTAN with the successful completion of extractables testing and the launch of its leachables studies.

Australian company Atmo Biosciences has received US FDA 510(k) clearance for its gas capsule system, meaning it can be marketed and sold in the country.

FivepHusion has announced the successful completion of the Phase 1 component of the Deflexifol at Relapse Trial, supported by the Kids with Cancer Foundation, an Australian-led study of a new brain cancer treatment for children.

Paradigm Biopharmaceuticals (ASX:PAR) has announced the acquisition of Proteobioactives, a company founded by Professor Peter Ghosh and based on his pioneering research into pentosan polysulfate sodium.

Firebrick Pharma (ASX:FRE) says it has secured commitments from qualifying investors for approximately $0.2 million through the issue of approximately 3.1 million new fully paid ordinary shares at an issue price of 6.3 cents per share.

Neuren Pharmaceuticals (ASX:NEU) has announced that the United States Patent and Trademark Office has allowed its patent application covering the use of NNZ-2591 to treat Pitt Hopkins syndrome.

Noxopharm (ASX:NOX) has announced that recruitment activities are progressing rapidly and on schedule for the HERACLES clinical trial.